24 November 2015 - Following approval for both of these indications by the EC earlier this year, the Company is voluntarily withdrawing the Marketing Authorization under the Nivolumab BMS brand name. This withdrawal has no impact for SQ NSCLC patients taking nivolumab since Opdivo is now approved for the treatment of SQ NSCLC, as well as for melanoma.

For more details, go to: http://news.bms.com/press-release/european-commission-approves-reconciliation-indications-nivolumab-under-opdivo-europea